Gabather AB Says has signed a consortium agreement for clinical development of its drug candidate GT-002 together with partner companies Pharmaterials, Smerud and CRST.
Cooperation starts in October and lasts until Phase 2a or a total of three years.
The agreement gives a net contribution from local EU authorities to cooperation of about 10 million Swedish crowns ($1.16 million).
Other costs are paid by the participating parties.
Source : reuters.com